ERBB2 and breast carcinoma: The current assessment of HER2 based on immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) performed on breast cancer tissues obtained through biopsies or surgeries is expensive, invasive, time-consuming, and lagging [7, 8].